Home/Filings/4/0001209191-23-018979
4//SEC Filing

Farwell Wildon 4

Accession 0001209191-23-018979

CIK 0001818794other

Filed

Mar 14, 8:00 PM ET

Accepted

Mar 15, 5:49 PM ET

Size

5.2 KB

Accession

0001209191-23-018979

Insider Transaction Report

Form 4
Period: 2023-03-14
Farwell Wildon
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2023-03-14$13.33/sh7,441$99,18992,655 total
Footnotes (2)
  • [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021, December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  • [F2]Includes 74,087 unvested RSUs.

Issuer

Dyne Therapeutics, Inc.

CIK 0001818794

Entity typeother

Related Parties

1
  • filerCIK 0001847941

Filing Metadata

Form type
4
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 5:49 PM ET
Size
5.2 KB